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Ataxia telangiectasia mutant (ATM) is an S/T-Q–directed kinase
that is critical for the cellular response to double-stranded breaks
(DSBs) in DNA. Following DNA damage, ATM is activated and
recruited by the MRN protein complex [meiotic recombination 11
(Mre11)/DNA repair protein Rad50/Nijmegen breakage syndrome
1 proteins] to sites of DNA damage where ATM phosphorylates
multiple substrates to trigger cell-cycle arrest. In cancer cells, this
regulation may be faulty, and cell division may proceed even in
the presence of damaged DNA. We show here that the ribosomal
s6 kinase (Rsk), often elevated in cancers, can suppress DSB-induced
ATM activation in both Xenopus egg extracts and human tumor cell
lines. In analyzing each step in ATM activation, we have found that
Rsk targets loading of MRN complex components onto DNA at DSB
sites. Rsk can phosphorylate the Mre11 protein directly at S676 both
in vitro and in intact cells and thereby can inhibit the binding of
Mre11 to DNA with DSBs. Accordingly, mutation of S676 to Ala can
reverse inhibition of the response to DSBs by Rsk. Collectively, these
data point to Mre11 as an important locus of Rsk-mediated check-
point inhibition acting upstream of ATM activation.
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Cells have evolved multiple pathways signaling DNA damagethat trigger DNA repair, cell-cycle arrest and, in the event
of irreparable damage, cell death. Among the various forms of
DNA damage, double-stranded breaks (DSBs) in DNA, gener-
ated by exposure to ionizing radiation and radiomimetic chemicals
such as neocarzinostatin (NCS), are the most lethal for cells (1).
DSBs often are repaired by homologous recombination during
the S and G2/M phases of the cell cycle, which involves the
meiotic recombination 11 (Mre11)/DNA repair protein Rad50/
Nijmegen breakage syndrome 1 (Nbs1) (MRN) complex and the
ataxia telangiectasia mutated (ATM) kinase (2, 3). The MRN
complex first recognizes sites of DNA damage and then pro-
motes binding of ATM to the DSB site. ATM, activated by
monomerization and autophosphorylation, phosphorylates down-
stream proteins including p53, checkpoint kinase 2 (Chk2), and
breast cancer 1, early onset (BRCA1) (4-7). These factors then
convey the signal to induce cycle arrest, apoptosis, or DNA repair
(8). Failure of this process results in genome instability, increasing
the risk of cancer, neurodegeneration, and other pathologies (9).
Ribosomal S6 kinase (Rsk), which functions downstream of
mitogen-activated protein kinase kinase (MEK) and ERK, is
frequently activated in cancer cells (10, 11). Rsk activation can
be promoted by multiple signaling pathways in cancer cells, in-
cluding those triggered by steroids, insulin, EGF, and estrogen
(10, 12–15). Additionally, Rsk activation can be triggered by
PKC signaling [via the PKC/rapidly accelerated fibrosarcoma
(RAF)/mitogen-activated protein kinases (MAPK) pathway],
which is activated by phorbol12-myristate13-acetate (PMA) (16,
17). Previous studies have found that Rsk2 is overexpressed in
50% of breast cancers and prostate tumors (18, 19), and Rsk
signaling has been implicated in the regulation of survival, an-
chorage-independent growth, and transformation of breast cancer
cells in culture (20). Rsk-specific inhibition (with BI-D1870 or
SL0101) significantly reduced proliferation of MCF7, PC3, or
LnCaP cancer cells (18, 19). Rsk also inhibits apoptosis in PC3
prostate cancer cells (21).
A hallmark of cancer cells is their ability to override cell-cycle
checkpoints, including the DSB checkpoint, which arrests the cell
cycle to allow adequate time for damage repair. Previous studies
have implicated the MAPK pathway in inhibition of DNA-dam-
age signaling: PKC suppresses DSB-induced G2/M checkpoint
signaling following ionizing radiation via activation of ERK1/2
(22); activation of RAF kinase, leading to activation of MEK/
ERK/Rsk, also can suppress G2/M checkpoint signaling (23).
Given its prominent role in multiple cancers, the MAPK
pathway is an attractive therapeutic target. Indeed, treatment of
melanoma using the RAF inhibitor vemurafenib has shown some
clinical success, as has treatment of nonsmall cell lung carcinoma
with MEK inhibitors (24). However, targeting components at the
apex of a signaling pathway may induce side effects caused by the
plethora of downstream effectors (25, 26). As a terminal kinase
in the MAPK pathway, Rsk may avoid these complications as
a potential target. Thus, there has been interest in targeting Rsk
for cancers with notable Rsk elevation (e.g., prostate cancers) (27).
Several Rsk-specific inhibitors have been described, including
SL0101 and BI-D1870 (18, 28, 29). Whether these or derivative
drugs will be clinically successful remains unclear. However, if Rsk
inhibition can reinstate DSB-induced checkpoint function, then
combination therapy of Rsk inhibitors with DNA-damaging agents
may be effective in inducing tumor cell arrest or death.
The precise mechanism underlying checkpoint inhibition down-
stream of MEK/ERK/Rsk signaling is not yet clear. One recent
paper has shown that, after doxorubicin-induced DNA damage
(both DSB and ssDNA breaks), Rsk can silence the G2/M
checkpoint by phosphorylating (and inhibiting) the Chk1 kinase
on S280 (the same site that can be targeted by protein kinase B/
Akt kinase) (30). However, another group has reported that
phosphorylation of this site on Chk1 enhanced its ability to en-
force the checkpoint by promoting its nuclear translocation (31).
We show here that Rsk signaling silences the DSB-induced
G2/M checkpoint by preventing activation of the ATM kinase.
Specifically, we have found that Rsk targets the Mre11 compo-
nent of the MRN complex by phosphorylating S676, thereby
preventing Mre11 binding to DNA. Mutation of S676 restored
ATM activation, even in the face of high Rsk activity, and rendered
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cells refractory to the checkpoint-inhibitory effects of Rsk. This
finding is consistent with a previous study showing that phosphor-
ylation on Mre11 is mostly inhibitory (32). Taken together, these
findings identify a locus of checkpoint regulation by Rsk and
support the idea of targeting Rsk for therapeutic benefit.
Results
Prostate Cancer Cells with High Levels of Endogenous Rsk Are Resistant
to DSBs. Rsk is highly expressed in many prostate cancer cell lines,
including PC3 and LnCaP cells, which appear to be highly de-
pendent on Rsk activity for growth and survival (19). We hy-
pothesized that Rsk might modulate the response of these cells
to DNA damage-induced checkpoint function. To evaluate this
hypothesis, we analyzed cell-cycle progression after DSB induction
in PC3 cells that endogenously express twice the level of Rsk
protein found in normal prostate tissue (19). Cells were arrested at
G1/S using double thymidine block and 4 h after release were
treated with PMA and/or SL0101, followed by NCS to induce
DSBs during the G2 phase. After drugs were washed away, cells
were incubated in fresh media for 16 h before DNA contents were
analyzed. As shown in Fig. 1A, cotreatment of cells with SL0101
and NCS resulted in much more robust G2/M arrest than seen
with NCS alone. Additionally, after PMA-induced Rsk activation,
the DSB-induced G2/M arrest was effectively overridden. We
obtained similar results in experiments in which Rsk1/2 were
knocked down using siRNA (Fig S1A). Taken together, these data
suggest that Rsk might inhibit the DSB checkpoint in PC3 prostate
cancer cells. To examine this possibility further, we stained PC3
cells for γ-H2AX, a downstream target of ATM. As shown in Fig.
1B, PC3 cells treated with SL0101 before NCS treatment dis-
played greatly increased γH2AX staining. These data strongly
suggest that high Rsk activity can suppress ATM-dependent G2/M
checkpoint signaling.
Although it has been reported that inhibiting ATM may en-
hance G2/M accumulation (33), inhibiting ATM decreased the
G2/M population in the cell lines we used (Fig S1B). This result
also is consistent with other published studies (34, 35).
To determine if Rsk is sufficient to confer resistance to DSB-
induced G2/M arrest, we overexpressed constitutively active Rsk2
in 293T cells, which have much lower endogenous levels of Rsk
than PC3 cells. As shown in Fig. 1C, Rsk-expressing cells were
considerably less sensitive to DNA damage than control cells. To
demonstrate G2/M checkpoint suppression, directly, we synchro-
nized HeLa cells in G1/S phase by double thymidine block and
treated them 4 h after release with PMA or SL0101 for 30 min and
with NCS for an additional 30 min. Three or five hours later, cells
were stained with anti–phospho-Histone H3 (PHH3) antibody. As
shown in Fig. S1C, NCS significantly reduced the number of pHH3-
positive cells by arresting cells in G2 phase. However, PMA treat-
ment greatly increased the pHH3-positive population (particularly
at 5 h), suggesting that the G2/M checkpoint had been silenced.
This checkpoint inhibition was reversed by cotreatment with
SL0101, confirming a role for Rsk in this silencing.
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Fig. 1. Rsk suppresses the DSB response in prostate
cancer. (A) PC3 cells were synchronized in G1/S
phase by double thymidine block. Four hours after
release, cells were treated with PMA or SL0101 as
indicated and then with NCS and were analyzed for
DNA content. n = 3 experiments. The effectiveness
of PMA and SL0101 in modulating Rsk activity was
shown by immunoblotting for the Rsk substrate, S6.
*P < 0.01; **P < 0.01. Error bars indicate SD. (B) PC3
cells grown on coverslips were treated with SL0101
or DMSO and then with NCS. Fixed cells stained for
γH2AX were examined by fluorescent microscopy
(20×). The average intensity of γH2ax staining for
more than 50 cells from at least seven random fields
was quantified with MetaMorph. *P < 0.01; **P <
0.01. (C) 293T cells transfected with FLAG-tagged
WT or constitutively active Rsk2 were treated with
NCS. DNA profiles of FLAG-positive sorted cells
were analyzed to quantify cells in G2/M. n = 3
experiments. *P < 0.05. Error bars indicate SD. P
values are derived from the Student t test.
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Rsk Suppresses the DSB Response by Inhibiting the Activation of ATM.
To identify the locus of Rsk action within the DSB-signaling
pathway, we assessed the status of the ATM kinase following
NCS treatment in cells overexpressing constitutively active Rsk2.
We found that after treatment with NCS these cells had reduced
ATM phosphorylation at S1981 (a hallmark of ATM activation)
but no change in ATM protein levels (Fig. 2A). Similarly, PMA
treatment markedly decreased ATM autophosphorylation at
S1981. However, ATM phosphorylation was restored when cells
were treated with both PMA and SL0101 (Fig. S2A). To dem-
onstrate further the down-regulation of ATM, we measured
phosphorylation of NBS1 at S343, a site known to be targeted by
ATM. As expected, phosphorylation of NBS1 was reduced in the
presence of PMA, consistent with Rsk-mediated reduction in
ATM activity (Fig. S2B). Accordingly, siRNA knock down of Rsk
in PC3 cells significantly increased ATM autophosphorylation in
response to NCS treatment (Fig. 2B). ATM autophosphorylation
is a very early event in the DSB response, and these data suggest
that Rsk acts either at or upstream of ATM. As is consistent with
an effect of Rsk signaling on ATM activity, HeLa cells treated
with PMA stained more weakly with antibody directed against
γH2AX than did untreated cells, and cotreatment with PMA and
SL0101 reversed the diminution in γH2AX staining (Fig. 2C and
Fig. S2C). HeLa cells transfected with FLAG-tagged constitu-
tively activated Rsk2 exhibited significantly less γH2AX staining
than nontransfected cells after NCS treatment (Fig. 2D and Fig.
S2D). This effect was reversed by treatment with SL0101 (Fig. 2D
and Fig. S2D). Collectively, these data suggest that Rsk signaling
suppresses both ATM activation and phosphorylation of its down-
stream targets, NBS1 and H2AX.
It is worth noting that ATM activation is detected robustly only
at the early phases of the DSB response (and thus the effects of
Rsk could not be detected later, at 24 h) (Fig. S2E). This situation
probably reflects checkpoint adaptation or recovery from DNA
damage, as is consistent with previous reports (36, 37). However,
cells were still phenotypically arrested at 24 h because either (i)
the remaining ATM activity/DSB response is sufficient to maintain
the checkpoint or (ii) checkpoint recovery lags behind DSB re-
sponse recovery because cells require time to resume the cell cycle
even though the upstream DNA-damage signals have waned.
The Moloney Sarcoma Oncogene/MAPK/Rsk Pathway Inhibits Binding
of the MRN Complex to dsDNA.To identify the direct targets of Rsk
responsible for inhibiting the DSB response, we used the Xen-
opus egg extract system, in which DSB checkpoint signaling can
be reconstituted in vitro. This system allows easy manipulation of
both DNA templates and Rsk signal components. Interphase
extracts prepared from Xenopus eggs (crude S extracts) were
treated with recombinant maltose-binding protein (MBP)-tagged
Moloney sarcoma oncogene (Mos) kinase, a strong upstream
activator of the MAPK pathway, leading to robust Rsk activation
(38). This treatment markedly inhibited autophosphorylation of
ATM induced by dsDNA without altering ATM levels. SL0101
treatment reversed this inhibition (Fig. 3A). To rule out the
possibility that signaling by other Mos-activated kinases might
cause the inhibition of the DSB response, we treated crude S
extracts with prephosphorylated constitutively activated Rsk, and
observed a similar decrease in ATM autophosphorylation (Fig.
3B). Because ATM must be recruited to the site of DNA break
by the MRN complexes before autophosphorylation and mono-
merization, we investigated the binding of ATM to dsDNA. We
immobilized biotin-tagged dsDNA on avidin beads to mimic sites
of dsDNA damage, incubated the beads with crude S extracts,
and retrieved DNA bead-associated proteins. We observed
a significant decrease in dsDNA-bound ATM after pretreatment
of extracts with Mos, whereas binding of another DNA damage-
response protein, Ku70, was unchanged (Fig. 3C). To rule out
the possibility that decreased ATM binding resulted from re-
duced ATM activity, we supplemented extracts with the ATM/
ataxia telangiectasia and Rad3-related protein (ATR) kinase in-
hibitor caffeine; this supplementation did not reverse the decrease
in ATM/DNA binding (Fig. 3D). Together, these data suggest that
Rsk functions upstream of ATM, affecting its recruitment to sites
of DNA damage.
Because ATM recruitment is preceded by recognition of DNA-
damage sites by the MRN complex, we investigated whether the
binding of the MRN complex to dsDNA is affected by Rsk. In-
deed, less Mre11 protein was associated with dsDNA in the crude
S extracts pretreated with Mos than with control MBP protein.
Moreover, SL0101 suppressed the effect of Mos (Fig. 3D). The
association of Mre11 with the beads was DNA dependent; an
excess of free DNA significantly decreased the levels of bead-
bound Mre11 (Fig. S3A). Moreover, treatment with either the
ATM inhibitor KU55933 or ATM/ATR inhibitor caffeine did not
reverse Rsk’s inhibition of Mre11 binding. This result strengthens
the suggestion that the observed effect on MRN complex/DSB
DNA assembly was not caused by feedback from downstream
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Fig. 2. Rsk suppresses the DSB response by inhibiting the activation of ATM.
(A) HeLa cells transfected with FLAG-tagged Rsk2 were treated with NCS,
lysed, and immunoblotted for phospho-ATM 1981. (B) Rsk1/2 knockdown
PC3 cells were lysed and immunoblotted for phospho-ATM 1981. Cells
treated with control siRNA were used as control. (C) HeLa cells grown on
coverslips and treated with PMA ± SL0101 and then with NCS were fixed,
stained, and examined for DAPI and γH2AX staining by fluorescence mi-
croscopy (20×). Average intensity of γH2ax staining from more than 50 cells
from 10 random fields was quantified with MetaMorph. *P < 0.01; **P <
0.01. Error bars indicate SD. (D) HeLa cells, transfected with FLAG-tagged
constitutively active Rsk2 were examined for γH2ax staining in FLAG-positive
and -negative cells by fluorescence microscopy (40×). Average intensity of
γH2ax staining from more than 40 FLAG-Rsk–positive and more than 300
FLAG-Rsk–negative cells from at least 18 random fields was quantified with
MetaMorph. Fold change in intensity of γH2ax staining in FLAG-Rsk–positive
relative to –negative cells was calculated. *P < 0.01. Error bars indicate SEM.
Statistical analyses were done by the Student t test. Representative images
from C and D are shown in Fig. S2 C and D, respectively.
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ATM signaling (Fig. 3D and Fig. S3A). To confirm these findings
in intact cells, we stained HeLa cells with anti-Mre11 antibody.
PMA activation of Rsk significantly reduced the formation of
Mre11/MRN foci, suggesting that Rsk indeed was suppressing the
binding of the MRN complex to the DSB DNA (Fig. S3B).
To rule out the possibility that Rsk disrupts the interaction
between Mre11 and other MRN complex components, we in-
vestigated binding of Mre11 to Nijmegen breakage syndrome 1
proteins (Nbs1) in egg extracts without added DNA. We did not
observe any effect of Rsk on the phys-ical interaction between
these two proteins (Fig. S3C), supporting the hypothesis that Rsk
interferes with Mre11 binding to DNA but not with the forma-
tion of the MRN complex itself. To confirm that Rsk mediates
suppression of ATM activation through the MRN complex, we
treated cells with H2O2, which activates ATM independently of the
MRN complex (39). Cells overexpressing Rsk displayed no change
in ATM activation following H2O2 treatment, in agreement with
our conclusion that Rsk silences ATM activation through suppres-
sion of MRN complex binding to DNA (Fig. S3D).
S676 on Mre11 is the Target of Rsk. To identify specific target(s) of
Rsk, we isolated DNA-bound proteins from crude S egg extracts
and incubated the precipitates with Rsk and radiolabeled ATP.
The one major protein band identified by SDS/PAGE and au-
toradiography was ∼85 kDa, which is the molecular weight of
Mre11, suggesting that Mre11 might be a direct target of Rsk
(Fig. S4A). This result was confirmed using His-tagged
recombinant Mre11, which could be directly phosphorylated by
Rsk2 kinase (Fig. 4A). To determine if the decreased MRN/
dsDNA binding was cause by phosphorylation of Mre11, we
prephosphorylated Mre11 with Rsk2 and then incubated Mre11
with crude S extracts for 15 min (to allow association of other
required factors) before precipitating the dsDNA. As shown in
Fig. 4B, prephosphorylation by Rsk2 reduced the binding of
Mre11 to dsDNA, suggesting that phosphorylation of Mre11
contributes to Rsk-mediated inhibition of the DSB response. To
identify the relevant sites of phosphorylation on Mre11, we
phosphorylated recombinant His-tagged Mre11 with Rsk in vitro
and analyzed the protein by mass spectrometry. We identified
four phosphorylated residues: 2, 641, 676, and 688. Although
none of those four sites was identical to the Rsk consensus site
RXRXXpS/T, Rsk can target nonoptimal sites (40). We mutated
each of the identified sites and performed in vitro Rsk assays
using the recombinant mutants. Although several of the sites
reduced phosphorylation, the single S676A mutation abolished
phosphorylation almost completely, suggesting that S676 is the
major site of in vitro phosphorylation by Rsk (Fig. 4C). Mre11
phosphorylation also was severely compromised by mutation of
S676 when radiolabeled ATP was added to lysates that had been
prepared from cells transfected with Rsk (Fig. S4B). Note that in
this experiment, cells were not serum starved before lysate pro-
duction, and thus WT or constitutively activated Rsk proteins
behaved similarly (because of the activation of the transfected WT
Rsk). As is consistent with our in vitro data, we successfully
detected endogenous Mre11 S676 phosphorylation in the pres-
ence of PMA or overexpressed WT/constitutively active Rsk with
an antibody that targeted phospho-S676 (Fig. 4 D and E). Phos-
phorylation induced by PMA was abrogated by cotreatment with
the Rsk inhibitor SL0101 (Fig. 4 D and E). In addition, we treated
Rsk-transfected cells with a DNA PK inhibitor to rule out the
possibility that Rsk might cause Mre11 S676 phosphorylation in-
directly by activating DNA PK (Fig. S5A). Although the DNA PK
inhibitor was effective against a known DNA PK substrate, Akt, it
did not inhibit phosphorylation of Mre11 downstream of Rsk (Fig.
S5B). Collectively, these data suggested that Rsk can phosphory-
late S676 of Mre11 both in vitro and in intact cells.
Phosphorylation of Mre11 on S676 Reduces Its Binding to dsDNA and
Is Responsible for Checkpoint Inhibition by Rsk. Mre11 has two po-
tential DBDs, and S676 is located within the second of these (Fig.
5A) (41, 42). Therefore, we speculate that phosphorylation of
Mre11 on S676 might directly disrupt its binding to dsDNA. As
shown in Fig. 5B, Mos treatment of egg extracts reduced binding
of WT Mre11 to DNA beads but had no effect on the S676A
mutant. Moreover, pretreating recombinant WT Mre11 with Rsk
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dsDNA. (A) Xenopus crude interphase extracts (S extracts) were treated with
control MBP or MBP-Mos and then with SL0101 or DMSO, and double-
stranded poly (dA-dT)70. Samples were analyzed for ATM autophosphor-
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with active RSK for 15 min before the addition of dsDNA. Samples were
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incubated with biotin-tagged dsDNA-bound avidin beads. The amount of
ATM bound to beads was analyzed by immunoblotting. DNA bound Ku70
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MBP-Mos or MBP ± caffeine or SL0101 and were incubated with biotin-tagged
dsDNA which was bound to avidin beads. The amount of Mre11 protein bound
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reduced the amount of DNA-bound Mre11, but this effect was not
seen when the S676A mutant was used (Fig. 5C).
Consistent with the role for Mre11 S676 phosphorylation in the
control of ATM by Rsk, we found that the ability of Mos to inhibit
DSB-induced ATM activation in Xenopus egg extracts was damp-
ened significantly by the addition of the S676A mutant Mre11 (Fig.
5D). Moreover, upon expression in 293T cells, the S676A mutant
conferred resistance to Rsk-mediated G2/M checkpoint inhibition,
whereas the control mutant (mutated at the other sites originally
seen by mass spectrometry, 2A/641A/688A) did not (Fig. 5E). We
further investigated whether Rsk directly inhibited the formation of
Mre11/MRN foci in Mre11-mutant cells. We knocked down en-
dogenous Mre11 in HeLa cells using shRNA and transfected cells
with shRNA resistant WT Mre11 or S676A. PMA treatment re-
duced the Mre11 foci in cells expressing WT Mre11 but not in the
cells expressing the S676A mutant (Fig. 5F and Fig. S6). Moreover,
SL0101 reversed the effect of PMA in the WT-expressing cells, as is
consistent with a role of Rsk in controlling the formation of Mre11/
MRN foci via phosphorylation of Mre11 S676 (Fig. 5F and Fig. S6).
Discussion
We have shown here that Rsk signaling impairs cell-cycle arrest by
the DSB-induced G2/M checkpoint by inhibiting the ATM pathway.
This effect appears to involve a failure to activate ATM through
MRN-mediated recruitment to sites of DNA damage. We found
that Mre11 protein, a core constituent of the MRN complex, was
phosphorylated by Rsk both in vitro and in intact cells. Furthermore,
through mutagenesis experiments, one of the identified phosphory-
lation sites, S676, was demonstrated to be essential for functionally
inhibiting Mre11. Together, these findings provide a mechanism for
Rsk-induced inhibition of DSB checkpoint function.
A recent paper investigating the role of Rsk in G2/M arrest
following doxorubicin treatment reported that Rsk could phos-
phorylate Chk1 at S280, the site that is targeted by Akt kinase to
inhibit Chk1 activity (30). However, a similar study showed that
the same phosphorylation on Chk1 had the opposite effect (31).
Our findings are distinct from these reports in demonstrating
that Rsk-mediated inhibition of ATM activation can be achieved
by targeting steps upstream of ATM activation. In addition, Rsk
can suppress G2/M checkpoint function following DSB in cells
knocked down for Chk1, suggesting that Rsk phosphorylation
of Mre11 contributes to DSB-induced G2 checkpoint silencing
independently of Chk1 (Fig. S7A).
The finding that phosphorylation on Mre11 at S676 inhibited
its binding to the DSB also is consistent with a previous report
demonstrating that mutation of eight SQ/TQ sites on Mre11,
including S676, undermined the negative feedback loop whereby
ATM terminates the checkpoint response by inhibiting DNA
binding by Mre11 (32). Our study strongly suggests that S676 is,
at least in part, responsible for such inhibition and that S676
phosphorylation can prevent binding of Mre11 to dsDNA not
only in Xenopus extracts but also in mammalian cells. In addi-
tion, we implicate Mre11 phosphorylation as a factor in a critical
checkpoint inhibitory pathway that results from high ambient
MAPK signaling in cancer cells. Interestingly, Di Virgilio et al.
suggested that ATM is not the only kinase responsible for the
phosphorylation of the observed eight SQ/TQ phospho-sites
(32). Indeed, it is possible that Rsk not only participates in
a checkpoint inhibitory pathway but also acts downstream of
ATM in the pathway of feedback inhibition. In other words, it
may be that ATM can inhibit Mre11 by activating Rsk. We note
that the converse cannot be true—i.e., Rsk cannot activate ATM to
phosphorylate Mre11—because ATM inhibition did not preclude
Rsk-mediated phosphorylation or inhibition of Mre11.
The DNA-damage response and its regulation have been shown
to play a critical role in tumorigenesis; the DSB-response pathway
can be turned off early in tumor development in multiple types
of cancer. This abrogation of checkpoint function prevents cell-
cycle arrest, leads to error-prone DNA replication, and promotes
accumulation of multiple cellular mutations (which can fuel can-
cer progression) (43, 44). Moreover, because the primary goal of
radiation therapy is the generation of abundant DSBs to induce
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permanent cell-cycle arrest and/or apoptosis, the overriding of
DSB-induced checkpoint function can undermine the utility of this
treatment modality. Indeed as shown in Fig. S7B, in the cells we
tested, up-regulation of Rsk rendered cells resistant to excessive
DSB-induced cell death. However, it should be noted that in some
radioresistant tumors the DSB response and DNA repair are up-
regulated rather than inactivated, leading to efficient repair
of radiation-induced DNA damage (45). Consequently, the ther-
apeutic benefit of inhibiting or activating the DSB response is
likely to vary depending on tumor type. This variance has clear
implications for Rsk as a target of tumor therapy. In cancer cells
that inhibit their checkpoint function through Rsk, Rsk inhibition
might be synergistic with ionizing radiation.
The consequences of inhibiting Rsk for cancer therapy extend
beyond the impact on cell-cycle checkpoints and DNA repair.
Recently, our laboratory reported that Rsk can phosphorylate
the apoptotic inducer Apaf-1 and thereby reduce its apoptotic
activity (21). Similarly, it has been reported that Rsk can inhibit
the action of Bax/Bad complexes, a pivotal mediator of cell death
following both chemotherapy and radiation (46). Therefore, at
least for tumors with high Rsk activity, inhibition of Rsk may
restore DNA damage-induced cell-cycle arrest while at the same
time removing the brake on apoptosis. In these tumors, Rsk
inhibitors may extend the utility of both irradiation and DNA-
damaging chemotherapeutics.
Materials and Methods
Detailed information on materials and protocols is given in SI Materials
and Methods.
Xenopus Extracts and DNA Immunoprecipitation. Cytostatic factor (CSF)
extracts and interphase extracts were prepared as previously described (38).
Detailed information is provided in SI Materials and Methods.
Immunostaining. HeLa cells were grown on coverslips, were treated with dif-
ferent drugs as described in Results, and were fixed with 4% (vol/vol) para-
formaldehyde for 20 min. Immunostaining was performed as described
previously (47) using anti-γH2AX antibody.
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SI Materials and Methods
Xenopus Extracts and DNA Immunoprecipitation. For extracts trea-
ted with DSB DNA, 5 μL of 0.01 mM dAdT dsDNA (70 nt) was
added to 50-μL extracts. Extracts were incubated at room tem-
perature. For DNA precipitations, 1 μL of biotin-tagged dsDNA
(0.25 mM) was bound to 25 μL of avidin beads for each reaction.
DNA-bound beads then were incubated with 100-μL extracts for
20 min at room temperature. Beads were removed from extracts
and washed four times with egg lysis buffer (250 mM sucrose, 2.5
mMMgCl, 1 mM DTT, 50 mM KCl, and 10 mMHepes, pH 7.7).
Cell Culture and Drug Treatments. 293T, HeLa, or MCF7 cells were
maintained in high-glucose DMEM medium supplemented with
10% FBS. PC3 cells were maintained in F12K medium. Cells
were grown to 90% confluence before treatment with drugs. For
SL0101 treatment, 1 μL of 100 mM SL0101 was added to 1 mL
of medium for a final concentration of 100 uM. Cells were
treated with SL0101 for 30 min. For phorbol12-myristate13-ac-
etate (PMA) treatment, 0.5 μL of PMA (50 ng/μL) was added to
1 mL of medium to make final a concentration of 25 ng/mL Cells
were treated for 30 min. For neocarzinostatin (NCS) treatment,
0.2 μL of NCS (500 ng/mL) was added to 1 mL medium to make
a final concentration of 200 ng/mL After treatment for 30 min,
cells were washed once with PBS.
Transfection and siRNA. FuGENE 6 (Roche) was used to transfect
cells with plasmids according to the manufacturer’s instructions.
Lipofectamine RNAiMAX (Invitrogen) was used to perform
siRNA transfections. siRNA targeted against ribosomal s6
kinase 1 (RSK1) and RSK2 as previously described (40) were
purchased from Sigma.
Plasmid Reagents and Antibodies. C-terminal HA-tagged meiotic
recombination 11 (Mre11) and N-terminal Flag-tagged RSK2
were cloned into pCDNA3 plasmid. Mre11 alanine mutants and
the constitutively active RSK2 707A mutant were generated by
site-directed mutagenesis. The antibodies against human Mre11
(Abcam), phospho-S6 Ser235/236 (Cell Signaling), phosphor-
histone H3 (Ser10) (Cell Signaling), actin (Santa Cruz), phos-
phor-Mre11 Ser-676 (Cell Signaling), goat anti-HA (Abcam),
His-probe (Santa Cruz), γH2AX Ser139 (Cell Signaling), human
ataxia telangiectasia mutant (ATM) (Abcam), phospho-ATM
Ser1981 (Epitomics), and anti-human/Xenopus Mre11 (Calbio-
chem) were obtained as stated.
The antibodies against Xenopus Nijmegen breakage syndrome
1 (Nbs1) and ATM were gifts from William Dunphy (California
Institute of Technology, Pasadena, CA).
The following drugs were used: PMA (Enzo Life Science), NCS
(Sigma), SL0101 (Calbiochem), and Ku55933 (Calbiochem).
Biotin-tagged ssDNA was purchased from Integrated DNA
Technologies. Biotin-tagged dsDNA was synthesized by anneal-
ing tagged ssDNA with its anti-sense DNA at 70 °C and gradual
cooling to room temperature.
Kinase Assay. For kinase assays in mammalian cell lysates, nickel-
agarose–bound Mre11-His was incubated with 2 μCi γ-[32P]ATP
in cytosolic lysates from mammalian cells transfected with RSK2
for 1 h at 30 °C. Beads then were removed and washed three
times in washing buffer [1 mM Hepes-KOH (pH 7.5), 1 mM
β-glycerophosphate, 15 mM KCl, 0.1% Nonidet P-40, 14.8 mM
imidazole, 500 mM NaCl, 1 mM NaVO3, and 5 μg/mL aprotinin/
leupeptin].
For the in vitro kinase assay, nickel-agarose–bound Mre11-His
protein was incubated in kinase buffer [10 mM Tris·HCl (pH
7.5), 0.1 mM ATP, 10 mM MgCl2, 1 mM DTT (pH 7.2)]
with 2 μCiγ-[32P]ATP and RSK2 kinase (Millipore). After
30 min at 30 °C, the beads were washed with washing buffer.
Analysis for all kinase assays was performed using SDS/PAGE
and autoradiography.
Immunoblot Analysis. For tissue culture, cells were cultured to 90%
confluence before harvesting with trypsin. Cells then were lysed with
extraction buffer [20 mM Hepes (pH 7.4), 150 mM NaCl, 12.5 mM
M glycerophosphate, 1.5 mM MgCl2, 2 mM EGTA, 10 mM NaF,
2 mM DTT, 1 mM Na3VO4, 20 μM aprotinin, 1 mM PMSF, and
0.5% Triton X-100]. The concentration of cell lysates was mea-
sured. Equal amounts of lysates were loaded for SDS/PAGE.
Proteins were transferred from gels to PVDF membrane and were
immunoblotted with antibodies. For large-molecular-weight pro-
teins such as ATM, low-voltage (50 V) was used in the overnight
transfer.
For Xenopus extracts, 5 μL of extract was mixed with 50 μL
SDS sample buffer. Extracts and samples were loaded for SDS/
PAGE, transferred from gels to PVDF membrane, and pro-
cessed for immunoblotting with antibodies.
FACS. 293T cells were treated with inhibitors as describe in Results
in the main text and after 22 h were fixed with 4% para-
formaldehyde for 20 min. Cells then were permeabilized with
0.2% Triton in PBS buffer. After washing, cells were incubated
with primary antibodies at 37 °C for 2 h and then with secondary
antibody for 45 min. Cells were washed with PBS, treated with
RNase for 15 min, and stained with propidium iodide (PI). Cell
profiles were analyzed by flow cytometry. Each experiment was
repeated three times, and the Student t test was applied to assess
statistical significance. Significance levels are indicated in Results
and figure legends.
Additional Information for Microscopy. For microscopy, a Zeiss
Axio Imager widefield fluorescence microscope equipped with
a mercury arc lamp (Zeiss HBO100 power supply and lamp
housing) was used. The filter cube sets were Chroma 31000v2
(excitation wavelength range: 325 nm–375 nm, beam splitter: 410
nm, emission wavelength range: 435 nm–485 nm) for DAPI;
Chroma 41017 (excitation wavelength range: 450 nm–490 nm,
beam splitter Q495LP, emission wavelength range: 500 nm–550
nm) for GFP; and Chroma 41004 (excitation wavelength range:
535 nm–585 nm, beam splitter 595 nm: emission wavelength
range, 610 nm–680 nm) for RFP. Objectives used were a Zeiss
20×/0.50 EC Plan-NeoFluar and a Zeiss 40×/0.75 EC Plan-Ne-
oFluar. The camera was a Hamamatsu Orca ER monochrome
cooled-CCD camera. The acquisition software was MetaMorph
Premier version 7.7.3.0. Fluorescent intensity in the original raw
images was quantified with MetaMorph. Blank areas within
images were selected as background during quantification. Im-
ages also were adjusted for contrast and pseudocolored in Meta-
Morph for presentation in figures.
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Fig. S1. (A) 293T cells were transfected with RSK1/2 siRNA. Forty-eight hours later, cells were treated with PMA for 30 min and then with NCS for another 30
min. (Left) Cells were collected after 16 h, and DNA profiles were analyzed by flow cytometry. (Right) The effectiveness of knockdown was analyzed by
Western blotting. Data from three experiments were combined. *P < 0.01; **P < 0.01. Error bars indicate SD. (B) HeLa cells were treated with ATM inhibitor for
30 min and then with NCS for another 30 min. Cells were collected at the indicated time points, and DNA profiles were analyzed by flow cytometry. Data from
three experiments were combined. *P < 0.01. Error bars indicate SD. (C) HeLa cells were synchronized in G1/S phase by double thymidine block. Four hours
after release, cells were treated with PMA or SL0101 for 30 min and then with NCS for another 30 min. Three or five hours later cells were collected and stained
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with anti–phospho-Histone H3 antibody (pHH3). The pHH3-positive cells were analyzed by flow cytometry. Data from three experiments were combined. *P <
0.001; **P < 0.01. Error bars indicate SD.
A
Co
ntr
ol
PM
A
PM
A+
SL
01
01
Co
ntr
ol
PM
A
PM
A+
SL
01
01
ATM 1981P
pRsk
Actin
250 kDa
85 kDa
46 kDa
-NCS +NCS
ATM
250 kDa
B
NCS
only
PMA
+
NCS
PMA
+SL0101
+NCS
Hoechstgamma-H2AX MergedC
MergedFlag-Rsk2gamma-H2AX
NCS+SL0101
NCS only
no NCS
pATM 1981
ATM
Actin
250 kDa
250 kDa
50kDa
NCS 30’ NCS 24h
 - + + + - + PMA
No NCS
 - + +
 -  - +  -  - +  -  - + SL0101
D E
pATM 1981
pNBS1 343
NBS1
pS6
100 kDa
100 kDa
250kDa
37kDa
 -  - + - - SL0101
PMA+ - ++ -
 - + + + NCS -
Fig. S2. (A) 293T cells were treated with PMA and SL0101 or with PMA alone for 30 min and then with NCS for another 30 min before harvesting. Cell lysates
were immunoblotted for phospho-ATM 1981. (B) HeLa cells were treated with PMA or SL0101 for 30 min and then with NCS for another 30 min before
harvesting. Cell lysates were immunoblotted for phospho-NBS1 Ser-343 and for phospho-ATM. (C) HeLa cells were stained with DAPI and rabbit anti-γH2AX.
The pattern of γH2AX staining was examined by fluorescence microscopy. Images were taken under a 20× objective. (D) HeLa cells were transfected with FLAG-
tagged constitutively active RSK2 and costained with mouse anti-FLAG and rabbit anti-γH2AX antibody. The pattern of γH2ax staining in FLAG-positive and
-negative cells was examined by fluorescence microscopy. Images were taken under a 40× objective. (E) HeLa cells were treated with PMA or SL0101 for 30 min
and then with NCS for another 30 min. Cells were harvested immediately or were cultured in regular medium for another 24 h before harvesting. Cell lysates
were immunoblotted for phospho-ATM 1981.
Chen et al. www.pnas.org/cgi/content/short/1306328110 3 of 6
B NCS
DAPI
Mre11
NCS+PMA Ctrl
MRE11 foci 
positive%
0
30
60
Control PMA
*
A
Empty
beads
  MBP   Input  Mos MBP  Mos
Free
DNA
85 kDa
KU55933
85 kDa
Mre11
Loading: Mre11
C
IgG
 -  - +
Nbs1IP:
Mos
100 kDa
75 kDaMre11
NBS1
Actin
FLAG-Rsk2
ATM
pATM 1981
75 kDa
100 kDa
250kDa
250kDa
50kDa
+  - - +
+ + -  - H2O2
Rsk2
D
Fig. S3. (A) Biotin-tagged dsDNA was bound to avidin beads and added to Xenopus crude S extracts pretreated with maltose-binding protein (MBP)-Mos or
with MBP and then KU55933 and were incubated for 20 min. In one of the reactions, free dsDNA was added to compete with the DNA on the beads. The
amount of Mre11 protein bound to beads was analyzed by immunoblotting. (B) HeLa cells were grown on coverslips and were treated with PMA for 30 min
and then with NCS for another 10 min before fixation. (Left) Cells were stained with DAPI and rabbit anti-Mre11. The pattern of Mre11 foci staining was
examined by fluorescence microscopy. Images were taken under a 40× objective. Cells with more than five clear Mre11 foci were counted as Mre11-positive.
(Right) Results from three experiments were combined. Fifty cells from at least 10 random fields were counted in each experiment. *P < 0.001. Error bas
indicate SD. (C) Nbs1 protein was immunoprecipitated from Xenopus extract pretreated with Mos or MBP. Mre11 protein bound to Nbs1 was immunoblotted.
(D) HeLa cells transfected with FLAG-tagged Rsk2 were treated with 0.9 mM H2O2 for 30 min before harvesting. Cell lysates were immunoblotted for phospho-
ATM 1981.
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analyzed by autoradiography. (B) 293T cells were transfected with WT Rsk or constitutively active Rsk (RSK CA). Cells were collected 2 d after transfection to
make lysates. Equal amounts of WT His-tagged Mre11 protein and the 676A mutant proteins were mixed with lysates, kinase buffer, and γ-[32P]ATP at 37 °C for
45 min. Radiolabeled Mre11 protein was analyzed by autoradiography.
A B
pAkt 407
Akt
50 kDa
50 kDa
50kDa
Actin
Ct
rl
NC
S
NC
S+
DN
A p
k i
nh
ibi
tor
pS6
FLAG-Rsk2
Mre11
pMre11 676
75 kDa
75 kDa
37 kDa
100 kDa
+  - - +
+ + -  - Rsk2
DNA PKi
Fig. S5. (A) HeLa cells transfected with active Rsk2 kinase were treated with DNA PKC inhibitor for 30 min before harvesting. Lysates were blotted for anti-
Mre11 Ser-676 antibody. (B) HeLa cells were treated with DNA PKC inhibitor for 30 min and then with NCS for another 30 min before harvesting. Lysates were
immunoblotted with anti-Akt Ser407 antibody to see whether phosphorylation of Akt by DNA PKc was inhibited.
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Fig. S6. HeLa cells infected with Mre11 shRNA were grown on coverslips and transfected with shRNA-resistant WT Mre11 or 676A mutant. Forty-eight hours
after transfection, cells were treated with PMA and SL0101 for 30 min and then with NCS for another 10 min before fixation. Cells were stained with DAPI and
rabbit anti-Mre11 antibody. The pattern of Mre11 foci staining was examined by fluorescence microscopy. Images were taken under a 40× objective. Shown
are representative images of more than 50 cells from at least eight random fields from three experiments.(See Fig. 5F for quantitation.) Yellow arrows indicate
Mre11 foci in the nuclei.
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Fig. S7. (A) 293T cells were treated with siRNA to knock down endogenous checkpoint kinase 1 (Chk1). Forty-eight hours later, cells were treated with PMA
and/or SL0101 for 30 min and then with NCS for another 30 min. Cells were grown in DMEM medium for 16 h before harvesting, and DNA profiles were
analyzed by flow cytometry. Data from three experiments were combined. *P < 0.01. Error bars indicate SD. Note that the knockdown of Chk1 had minimal
effect on the response to NCS, possibly because the ATM/Chk2 pathway, the primary pathway for the dsDNA-break response, remained intact. (B) HeLa cells
were transfected with constitutively active Rsk2 kinase. After 36 h, cells were treated with 200 ng/mL NCS for 1 h. Cells were grown in DMEM medium for
another 48 h before harvesting. DNA profiles were analyzed by flow cytometry, and the sub-G1 population was analyzed. Data from three experiments were
combined. Error bars indicate SD.
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